Loading...
Topiramate can reduce heavy drinking days among patients who aspire to quit drinking. This medication affects glutamate receptors, especially those containing the kainite GluK1 subunit encoded by GRIK1, and a GRIK1 polymorphism has been associated with fewer adverse topiramate effects. In a 12-week, federally funded study, 138 heavy drinkers wishing to reduce drinking to safe levels (62% male; 62% employed full time) were genotyped for C and A alleles at rs2832407 and randomized to topiramate (dosed progressively to 200 mg/day; mean, 173 mg/day) or placebo.
All patients received medical management and brief psychosocial interventions at nine visits. Despite high lifetime prevalence of depression, only eight patients had current diagnoses of …